Stocksigma LogoStocksigma Logo

ChrysCapital Takes Control of Evonile Pharma; Expands into Cardiology and Ophthalmology

Following ChrysCapital's acquisition of a controlling 70.68% stake, Evonile Pharma (formerly Novartis India) reported its Q2 FY27 and H1 FY27 results under

ChrysCapital Takes Control of Evonile Pharma; Expands into Cardiology and Ophthalmology

Novartis India Ltd · Press Release · 04 Nov 2026, 1:31 am

ChrysCapital Takes Control of Evonile Pharma; Expands into Cardiology and Ophthalmology Following ChrysCapital's acquisition of a controlling 70.68% stake, Evonile Pharma (formerly Novartis India) reported its Q2 FY27 and H1 FY27 results under a revamped direct-distribution business model. Q2 FY27 revenue from operations reached ₹56.1 crore, while operating EBITDA stood at -₹31.8 crore due to upfront investments and one-time transition costs. For H1 FY27, revenue stood at ₹159.9 crore with a net loss of ₹45.3 crore. Strategically, the company expanded beyond its core therapy areas by acquiring Minipress XL (cardiology) and entering into an ophthalmology in-licensing agreement.

Original exchange filing (PDF)

More announcements from Novartis India Ltd

All Novartis India Ltd announcements